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ABSTRACT   
After failure of erythropoiesis-stimulating agents (ESA), Lenalidomide (LEN) yields red 
blood cells (RBC) transfusion independence (TI) in 20-30% of lower risk non-del5q MDS. 
Several observations suggest an additive effect of ESA and LEN in this situation. We 
performed a randomized phase III study in 131 RBC transfusion-dependent (TD, median 
transfusion requirement 6 RBC units/8weeks) lower risk ESA-refractory non-del5q MDS. 
Patients received LEN alone, 10mg/day, 21 days/4 weeks (L arm) or LEN (same schedule) + 
erythropoietin (EPO) beta, 60,000U/week (LE arm).  
In an intent-to-treat (ITT) analysis, erythroid response (HI-E, IWG 2006 criteria) after 4 
treatment cycles (primary endpoint) was 23.1% (95% CI: 13.5-35.2) in the L arm and 39.4% 
(95%CI: 27.6-52.2) in the LE arm (p=0.044), while RBC transfusion independence (TI) was 
reached in 13.8 and 24.2% of the patients in the L and LE arms, respectively (p=0.13). 
Median response duration was 18.1 and 15.1 months in the L and LE arms, respectively 
(p=0.47). Side effects were moderate and similar in the 2 arms. Low baseline serum EPO 
level and a G polymorphism of CRBN gene predicted HI-E. 
Combining LEN and EPO significantly improves erythroid response over LEN alone in lower 
risk non-del5q MDS patients with anemia resistant to ESA.
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INTRODUCTION 
Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders characterized by 
ineffective hematopoiesis leading to blood cytopenias and a variable risk of evolution to acute 
myeloid leukemia (AML)
(1)
. 
In International Prognostic Scoring System (IPSS)
(2),(3)
 Low or Intermediate-1 risk patients 
(“lower risk” MDS), the risk of AML progression is relatively low, survival generally 
prolonged, and treatment of anemia is the main therapeutic challenge in most cases. In the 
absence of isolated chromosomal 5q deletion (del5q), erythropoiesis-stimulating agents 
(ESA) give 30 to 50% erythroid responses, with a median response duration of about 2 
years
(4),(5),(6),(7),(8)
. 
Second line treatments after relapse or resistance to ESA include hypomethylating agents, 
yielding response rates between 25 to 35%
(9)
, while various other agents are currently being 
evaluated, including lenalidomide (LEN). 
LEN, a thalidomide analogue, yields 60 to 70% erythroid response (HI-E) and transfusion 
independence (TI) in lower risk MDS patients with del5q
(10),(11),(12)
, and is approved in this 
situation in many countries. In lower risk MDS patients without del5q resistant to ESA alone, 
LEN yields lower TI rates of 20% to 30%
(10),(13),(14),(15)
. However, our recent clinical 
experience suggested that the response rate to LEN could be increased by the addition of 
ESA
(14)
. 
To analyze more precisely this finding, we designed a phase III prospective open label 
randomized trial comparing LEN alone and LEN combined to erythropoietin (EPO) as second 
Toma et al.  6 
line treatment in non del5q RBC transfusion-dependent lower risk MDS patients with primary 
or secondary resistance to ESA.  
METHODS 
Patients 
Main inclusion criteria were: (i) MDS according to World Health Organisation (WHO) 2008 
criteria
(16)
, with Low or Intermediate-1 IPSS and ECOG status ≤2, (ii) no del5q based on 
conventional chromosomal or (if less than 20 mitoses were obtained) FISH analysis, (iii) 
RBC transfusion dependence (TD) ≥4 packed RBC units during the 8 weeks before inclusion 
(administered at hemoglobin levels <9g/dl), (iv) no erythroid response to epoetin (≥60,000 
Units/week) or darbepoetin (≥250 µg/week) administered during at least 12 consecutive 
weeks (i.e. a sufficient treatment duration to assess response according to most studies and 
recommendations)
(17)
 or relapse after an initial response, both defined according to 
International Working Group (IWG) 2006 criteria
(18)
, (v) platelet count >50G/L and absolute 
neutrophil count (ANC) >0.5G/L, and (vi) written informed consent.  
Patients receiving chelation therapy were eligible if chelation was continued at similar 
dosage, but onset of chelation therapy was not allowed during the trial. 
The study was approved by an ethics committee (CPP Ile-de-France X) and registered at 
clinicaltrials.gov (NCT01718379), EudraCT number 2008-008262-12.  
Study design 
This was a two-parallel arms open multicenter phase III clinical trial. Randomization between 
the two arms (1:1) was centralized and performed at the Unité de Recherche Clinique, Hôpital 
Cochin (Paris), using computerized lists based on permutation blocks stratified by centers. 
Patients were randomized between the LEN (L) arm: LEN alone 10 mg/day for 21 days every 
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28 days, and the LEN plus EPO (LE) arm: same LEN schedule combined to epoetin beta 
(60,000 units/week) (Figure 1). Celgene (Summit, NJ, USA) and Roche (Basel, Switzerland) 
provided Lenalidomide and epoetin beta, respectively, for the study, along with a research 
grant, but were not involved in data analysis and reporting. 
Blood counts were monitored weekly during the first four months of treatment, and every two 
weeks thereafter. The LEN dose was reduced to 5mg/day if ANC decreased below 1G/L 
and/or platelets below 50G/L, with further dose reductions to 5mg every other day and 5mg 
twice a week. The use of G-CSF was not allowed in case of neutropenia, due to its potential 
effect on the erythroid lineage when combined to an ESA
(5)
. 
Responders after 4 cycles were planned to continue the same treatment until relapse. A new  
bone marrow aspirate and cytogenetic analysis were performed after 4 cycles, and then every 
6 months in responders. 
 
Assessment of response and safety 
The primary endpoint chosen for the trial was HI-E according to IWG 2006 criteria
(18)
 after 4 
treatment cycles, i.e. reduction of RBC transfusions of at least 4 units during the 8 weeks 
prior to evaluation compared to the pretreatment period, for transfusions performed at 
hemoglobin levels <9g/dL. 
Secondary endpoints were TI, defined by the absence of RBC transfusion during the 8 weeks 
before evaluation, HI-E duration, time to progression to higher risk MDS or AML, and 
treatment safety. Adverse events were assessed using NCI-CTC version 3.0. 
All responses were blindly reviewed by an independent committee (composed of Dr V. 
Santini, Firenze, Italy, and Dr A. Giagounidis, Dusseldorf, Germany). 
CRBN polymorphism  
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Genetic studies were performed on marrow genomic DNA collected at inclusion. Cereblon 
(CRBN) gene A>G polymorphism located in the 5’UTR was analyzed, as previously 
described
(19)
.  
Sample size justification 
Sample size computation was based on the primary endpoint, assuming a response rate of 
30% and 57% in the control and experimental arms, respectively, based on previous findings 
with LEN alone and LEN combined to an ESA
(13),(14)
. With a type I and type II error rates 
fixed at 0.05 and 0.20, respectively, a minimum of 63 patients had to be enrolled in each 
randomized arm, based on a two-sided chi-square test with continuity correction.  
 
Statistical analysis 
Summary statistics were reported as median [interquartile range, IQR] for continuous 
variables and percentages otherwise. Analysis was based on the intent-to-treat (ITT) principle, 
including all patients allocated to their randomized arm whatever the treatment actually 
administered, except in case of consent withdrawal. All patients without response evaluation 
at 4 courses (primary endpoint) were considered as failures; such a simple imputation was 
used in all the manuscript unless specified in the text. Reasons for patient discontinuation that 
could be informative about treatment effectiveness were tabulated. Sensitivity analyses to 
such an assumption were then performed, assuming failure in one arm and response in the 
other arm. The response rate was estimated with 95% confidence interval (95%CI), compared 
between the randomized arms by the Chi-square test. Multivariate logistic regression was then 
performed to assess the prognostic set of baseline characteristics of the patients. Treatment-
by-covariates interactions were tested using the Gail and Simon statistics
(20)
. Time to failure 
data (response duration) were analyzed using Kaplan-Meier estimate and log-rank test. 
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All statistical tests were two-sided, with p-values of 0.05 or less denoting statistical 
significance. All analyses were performed on SAS 9.3 (SAS Inc, Cary, NC) and R version 
3.0.2 (2013-09-05) (http://www.R-project.org/) packages. 
 
RESULTS 
Baseline patient characteristics  
132 patients from 34 French centers were included from July 2010 to June 2012, 66 patients 
per treatment arm. One patient withdrew consent before the onset of treatment, and the ITT 
analysis was therefore performed in the 131 remaining patients. Baseline characteristics of the 
two arms are summarized in Table 1. 
Median age at inclusion was 73 years [IQR: 64-77] and M/F ratio was 2. According to WHO 
classification, there were 57 (43.5%) refractory anemia with ring sideroblasts (RARS), 24 
(18.3%) refractory cytopenia with multilineage dysplasia and ring sideroblasts (RCMD-RS), 
22 (16.7%) refractory anemia with excess blasts type 1 (RAEB1), 15 (11.5%) refractory 
cytopenia with multilineage dysplasia (RCMD), and 13 (9.9%) unclassified MDS (MDS-U).  
According to classical IPSS, 57 (43.5%) and 74 (56.5%) patients had Low and Intermediate-1 
risk, respectively. The median number of RBC units administered during the 8 weeks before 
inclusion in this series was quite high, i.e. 6 units [IQR 4-8]. Most (n=110, 84.0%) patients 
had favorable cytogenetics according to classical IPSS, while no patient had unfavorable 
cytogenetics. Median serum EPO level was 225.5 U/l [IQR: 69-498.5]. Eighty-one (61.8%) of 
the patients had primary resistance to ESA, and 50 (38.1%) had relapsed after an erythroid 
response (Table 1).  
Twenty-one patients (16.0%), 11 in the L arm and 10 in the LE arm, were also refractory to 
azacitidine administered after ESA failure, and were included after a wash-out period of at 
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least 3 months. At inclusion, 62 (47.3%) patients were receiving iron chelation with 
deferasirox. 
 
Treatment courses and observed responses 
A total of 32 patients did not receive the 4 planned courses, 16 in each randomized arm, due 
to adverse events (n=21), early death (n=4), investigator’s or patient’s decision (n=5), suicide 
(n=1), loss-to follow-up (n=1). One patient (LE arm) did not receive any treatment because of 
early death, 10 patients received only one course (5 in each randomized arm), 10 patients 
received two courses (3 in the L arm and 7 in the LE arm) and 11 patients received three 
courses (8 in the L arm and 3 in the LE arm) (Figure 2).  
Among the 99 (75.6%) patients who received at least 4 cycles of treatment, 49 patients in the 
L arm and 50 patients in the LE arm, HI-E after 4 cycles was observed in 15 (30.6%) patients 
in the L arm and 26 (52%) patients in the LE arm, while TI was achieved in 25 patients, 
including 9 (18.3%) and 16 (32%) in the L and LE arm, respectively.   
 
ITT analyses 
Based on the ITT analysis, HI-E after 4 cycles was 23.1% (15/65) in the L arm (95%CI: 13.5-
35.2) and 39.4% (26/66) in the LE arm (95%CI: 27.6-52.2; p=0.044 by the Chi-square test). 
Sensitivity analyses mostly reached similar conclusions (Table 2). TI was achieved in 13.8% 
(9/65) and 24.2% (16/66) of the patients in the L and LE arms, respectively (p=0.13 by the 
Chi-square test). The median time to erythroid response was estimated at 4 months in both 
arms. In patients who achieved transfusion independence, the mean peak increase in 
hemoglobin level compared to baseline was 1.8 g/dL (range 0.5-2.5) and 2.6 g/dL (range 0.5-
8.2) in the arm L and LE, respectively, with no significant difference between the two arms.    
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Seven (33%) of the 21 patients with baseline cytogenetic abnormalities achieved HI-E after 4 
cycles, but none of them achieved cytogenetic response.  
Among the 58 non-responders after the 4th cycle, who therefore discontinued treatment, late 
responses were observed in 2 patients (one in each arm), 4 and 6 weeks after evaluation in the 
L and LE arm, respectively. However, they were not included as responders for subsequent 
analyses. 
Relapse after erythroid response occurred in 7 of the 15 responders in the L arm and in 13 of 
the 26 responders in the LE arm. Median response duration was estimated at 18.1 months 
(95%CI: 7.6-NA) in the L arm, and 15.1 months (95%CI: 10.5-NA) in the LE arm (p=0.64 by 
the log-rank test) (Figure 3). Fourteen patients (7 in each arm) were still responders at the end 
of the study (i.e. at 2 years), 12 of them (5 in L arm and 7 in LE arm) being TI. Median TI 
duration was 18.5 months (95%CI: 12.69-NA) in the L arm, and 11 months (95%CI: 6.07-
NA) in the LE arm (p=0.31 by the log-rank test).  
 
Prognostic factors of response  
None of the following pretreatment factors: gender, age, WHO classification, cytogenetics 
(according to classical IPSS), classical IPSS, type of ESA resistance (primary or secondary) 
had any significant impact on HI-E in the two treatment arms (Table 3). By contrast, baseline 
serum EPO level below 100 UI/l (OR= 3.3, 95%CI: 1.35-7.9; p=0.0087) and presence of the 
G allele at CRBN rs1672753 (OR= 2.6, 95%CI: 1.09-6.3; p=0.032) were associated with a 
better response rate (Table 3). When considered jointly with the randomization arm into a 
multivariate logistic model based on the 99 patients who were tested for CRBN rs1672753 
polymorphism, both the treatment arm (OR= 5.0, 95%CI: 1.64-15.1; p=0.0047) and baseline 
serum EPO level (OR= 4.05, 95%CI: 1.3-12.6; p= 0.016) were found to add predictive 
information to each other (Table 4). 
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We then searched for treatment-by-covariates interaction to assess whether the difference in 
HI-E response rate after 4 cycles between the 2 randomized arms depended on baseline 
patient characteristics. No evidence of any difference in the benefit of LE was found 
according to those characteristics except for RBC transfusion requirement, where the benefit 
of LE was restricted to patients who had received, over the 8 weeks prior to inclusion, 4 RBC 
units (OR= 6.6, 95%CI: 2.08-21.4) compared to those who had received >4 RBC units 
(OR=1.32, 95%CI: 0.87-2.01) (p=0.010 by the Gail and Simon test) (Figure 4). Thus, in the 
39 patients who had received only 4 RBC units in the 8 weeks before inclusion (18 patients in 
L arm and 21 patients in LE arm), the TI rate was significantly higher in the LE arm (10/21 
patients, 47.6%) than in the L arm (3/16 patients, 18.7%) (p=0.04).  
Of note also that for karyotype, the benefit of LE appeared to be restricted to patients with 
favorable cytogenetics (representing 84% of the patients), with borderline significance 
(P=0.056 by the Gail and Simon test) (Figure 4). 
Finally, in the 50  patients with serum EPO levels ≥ 100 U/L there were 5/24 (21%) erythroid 
responses in the L arm and  10/26 (38%) in the LE  arm (p=0.10). 
 
Toxicity 
Hematological and non hematological toxicity was comparable in the two treatment arms. 
Before the end of the fourth cycle, grade 3 and 4 non hematological adverse events (AEs) 
were observed in 25% of the patients, including deep vein thrombosis (DVT) in 4 patients (3 
in the L arm and 1 in the LE arm) (Table 4), while grade 3 or 4 myelosuppression occurred in 
25% of the cases and included neutropenia in 21% and 18% of patients in the L and LE arm, 
respectively, and thrombocytopenia in 3% and 7% of patients, respectively, with no 
difference between the two arms (Table 5).  
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During the first 4 cycles, the dose of LEN was reduced in 31% and 36% of the patients in the 
L and LE arm, respectively, and the mean daily dose of LEN administered was 8.4 mg in both 
arms. After the 4th cycle, LEN doses had to be reduced in 50% and 57% of responders in the 
L and LE arm respectively, and the mean daily doses of LEN administered were 8.5 mg in 
arm L and 8,1 mg in arm LE. 
 
DISCUSSION  
In this randomized study, LEN combined with EPO induced a significantly higher erythroid 
response rate than LEN alone in ESA-resistant RBC TD lower risk MDS without del5q. The 
estimated HI-E response rate among all the population was 39.4% in the LE arm compared to 
23.1% in the L arm, and these figures reached 52% and 30.6%, respectively, in patients who 
received at least 4 cycles of treatment. However, RBC-TI rates were not significantly 
different between the 2 treatment arms (24.2% in the L arm versus 13.8 % in the LE arm, 
p=0.13). 
All patients included in the study could be considered resistant to ESA, combined or not to G-
CSF or were in relapse after an initial response. Indeed, although some responses to ESA (+/- 
G-CSF) may occur after more than 12 weeks, this is relatively rare, and most treatment 
guidelines use a 12 weeks period of treatment with at least 60,000 units of EPO or 250 µg of 
darbepoetin per week to define ESA resistance
(6),(21)
.
 
 
The rationale for combining an ESA to LEN treatment was based on the hypothesis that LEN 
could restore sensitivity of MDS erythroid progenitors to EPO. Biological studies have 
demonstrated that LEN increases the expansion of normal mature erythroid progenitors of 
CFU-E type in the presence of EPO
(22)
. The Cereblon protein, encoded by the CRBN gene, is 
the molecular target of LEN and a substrate receptor of CRBN-CRL4 E3 ubiquitin ligase 
complex. Recent evidence shows that LEN binding to Cereblon induces the proteosomal 
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degradation of casein kinase 1A, a protein encoded by CSNK1A1 located in 5q33.1 in 
myeloid cells with a del5q, while Cereblon targets in non del5q MDS remain to be 
determined
(23)
. Thus, the mechanism of action of LEN is still unclear in these cells. However, 
LEN may directly improve EPO receptor signaling in non del5q cells by inhibiting the protein 
tyrosine phosphatase CD45, leading to the reversal of CD45-induced inhibition of EPO-
R/STAT5 signaling, and also by improving the membrane lipid raft integrity, and thus the 
EPO receptor platform
(24),(25)
. A clinical benefit of LEN combined to ESA in lower risk MDS 
without del5q resistant to ESA alone had been observed in a French non randomized 
compassionate program, where 36% and 55% of the patients who received LEN alone and 
LEN combined with an ESA, respectively, achieved HI-E
(14)
. In another report from Moffitt’s 
center
(26)
, 4 of 19 (21%) lower risk MDS patients resistant to an ESA alone and to LEN alone 
responded to a LEN+ESA combination. 
Our response rate in the L arm was apparently somewhat lower than that obtained by Raza et 
al.
(13) 
 in a similar population (where RBC TI was achieved in 26% of the cases, compared to 
13.9% in our hands). However, in Raza et al’s study(13), ESA resistance was not documented 
in all patients (contrary to the present study). In that study
(13)
, patients who fulfilled our 
inclusion criteria (at least 4 RBC concentrates administered for Hb<9g/dL in the 8 weeks 
preceding study treatment) had a TI rate of 17%, similar to our results in the L arm.  In 
another recent study using LEN alone (MDS 005 study)
(15)
 in a similar population,  so far 
presented only in abstract form, RBC-TI was achieved in 26.7% of the patients. There was no 
RBC minimal transfusion requirement in Raza et al. study
(13) 
and a minimal transfusion 
requirement of 1.5 RBC units/28 days in MDS-005 study
(15)
,  compared to  4 units/8 weeks in 
the present study, possibly explaining the higher transfusion burden we  observed .  
In previous studies of lower risk MDS patients without del5q treated with LEN
(13),(14),(26)
, 
TD<2 units/month, platelets>150G/L, shorter duration of MDS, lower LDH level, favorable 
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karyotype
(13)
, lower serum EPO level
(26)
, and more favorable WHO classification
(14)
 were 
associated with higher HI-E. In our study, baseline EPO level was the only conventional 
factor predicting HI-E, and it was the only prognostic factor in multivariate analysis. We also 
confirmed the predictive value for HI-E of a G polymorphism in the 5’ UTR of the CRBN 
gene
(19)
 in univariate analysis. The predictive value of this G polymorphism should however  
be confirmed in an external cohort. In addition, reasons for this possible impact of CRBN 
rs1672753 on response to LEN, with or without EPO, in MDS cells remain to be identified. 
We also found that only patients with favorable karyotype according to conventional IPSS 
seemed to benefit from the addition of EPO to LEN. However, this cytogenetic category 
represented 84% of the patients included. The absence of cytogenetic responses after 4 
months in patients with baseline cytogenetic abnormalities in our study may support a 
different mechanism of action of the drug in MDS without del5q and  MDS with del5q where 
LEN often leads to cytogenetic response
(27)
.  
Response duration and TI duration  did not significantly differ between the 2 arms (median 
duration of 18.1 versus 14.6 months, and 18.5 and 11 months in the L and LE arm, 
respectively). By comparison, median TI duration with LEN alone was 10 months in Raza et 
al.'s study
(13)
, 8.2 months in Santini et al.'s study
(15)
. 
Side effects were similar in the 2 arms. Severe neutropenia and thrombocytopenia with LEN 
are less frequent and less profound in non del5q than in del5q patients. In Raza et al’s 
study
(13)
, the incidence of grade 3 or 4 neutropenia and thrombocytopenia was 25% and 20% 
respectively, with little difference observed between patients receiving the 10 mg daily and 
21-day lenalidomide schedule. The incidence of grades 3 or 4 neutropenia and 
thrombocytopenia was similar in our study, 24% and 25% respectively, and those cytopenias 
were the major reasons for early treatment discontinuation. Still, about 20% of the patients 
had early protocol discontinuation due to side effects, mainly cytopenias, and the dose of 
Toma et al.  16 
LEN had to be reduced in 31% and 36% of the patients in the L and LE arm, respectively, 
also due to cytopenias. These results suggest that a daily dose of LEN of 10mg during 3 
weeks every 4 weeks may be too high in a substantial proportion of the patients. A lower 
starting dose may have to be considered in future studies, in order to avoid early 
discontinuation by many patients. Management recommendations, based to some extent on 
those published for LEN in lower risk MDS with del 5q
(28)
 could also be useful. In MDS 005 
study
(27)
, grade 3-4 neutropenia and thrombocytopenia were reported in 62% and 36% of the 
patients,  respectively. 
 In our study, non hematological grade 3 and 4 toxicity was rare and included DVT in 3% of 
patients. Of note, the addition of high dose EPO did not increase the incidence of thrombotic 
events. 
Our current results with LEN and EPO appear at least equivalent to those reported in lower 
risk MDS without del5q resistant to ESA treated with hypomethylating agents, in our 
experience
(29)
 and in a Nordic study
(30)
. Interestingly, we found in lower risk MDS without 
del5q resistant to ESA that the addition of EPO did not improve the response rate to AZA
(29)
 
(manuscript in preparation). Other treatments in this situation have yielded only modest 
results. Immunosuppressive treatment with anti-thymocyte globulin with or without 
cyclosporine or with alentuzumab can yield response rates i.e. TI up to 30 to 40%, but in 
highly selected patient populations
(31),(32)
. Among innovative agents, the glutathione-S-
transferase P1-1 (GSTP1-1) inhibitor Ezatiostat and the MAP kinase inhibitor ARRY 614 
both gave a 29% erythroid response rate in heavily pretreated lower risk MDS without 
del5q
(33),(34)
, while early results using drugs with TGF beta pathway ligand traps (ACE 011 
and ACE 536)  appear promising
(15),(35)
. 
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A possible weakness of our work is that we chose HI-E according to IWG 2006 criteria, but 
not RBC-TI, as primary study endpoint, and that the patient number was not powered on the 
RBC-TI endpoint. Achieving TI, and not only a significant reduction of transfusion 
requirement, may indeed be considered as a better endpoint from a clinical perspective, and 
most recent clinical studies in lower risk MDS have chosen TI as primary endpoint, an 
endpoint that may also be required by health agencies like FDA and EMA 
(13),(27)
. There was 
indeed  no significant difference in TI rates in the whole patient series between the L and the 
LE arm. However, in this very heavily transfusion dependent population, when we restricted 
the analysis to patients who had received only 4 RBC units/8weeks before inclusion, TI rates 
were significantly higher in the LE arm than in the L arm (47% versus  16%, p=0.04). 
In conclusion, our prospective phase III randomized study shows that a LEN plus EPO 
combination can yield higher erythroid response rates than LEN alone in lower risk MDS 
without del 5q resistant to ESA. This did not translate into a significant improvement of RBC-
TI rate, possibly due to the insufficient size of our patient population or to the high 
transfusion burden in our patients, as TI rate differences were significant between the 2 
treatment arms when the analysis was restricted to patients who did not receive more than 4 
RBC units in the 8 weeks before inclusion. Tolerance of this treatment association was 
generally acceptable, although combinations using a lower initial dose of LEN may have to be 
explored to avoid early treatment discontinuation in a substantial proportion of the patients.  
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FIGURE LEGENDS  
 
Figure 1 : GFM-LENEPO 2008 study  
Treatment plan 
(registered at clinicaltrials.gov (NCT01718379), EudraCT number 2008-008262-12) 
 
Figure 2 : CONSORT 2010 flow diagram of the GFM-LENEPO 2008 study 
 
Figure 3: Response duration according to the randomization arm 
Reported figures are the number of exposed patients in each randomized arm over time 
L, Lenalidomide ; LE, Lenalidomide + Erythropoietin.  
 
Figure 4: Search for treatment-by-subset interactions 
This forest plot displays the estimated effect of randomized arm on response rate (LE vs L) in 
patient subsets, using the odds ratio (OR) as the measure of effect. The heterogeneity in OR 
across the subsets are tested by the Gail and Simon test. 
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Table 1: Baseline Patient Characteristics overall and according to the randomization 
arm 
Patient characteristics 
Randomized Treatment arms 
All 
(n=131) 
L arm (n=65)  LE arm (n=66) 
Age, median (IQR) 73 [64-77] 73.5 [68-76] 73 [64-76] 
M/F 1.6 2.6 2 
WHO classification, N (%)    
RARS 25 (39.7) 32 (48;5) 57 (43.5) 
RCMD-RS 16 (25.4) 8 (12.1) 24 (18.3) 
RAEB1 7 (11.1) 15 (22.7) 22 (16.7) 
RCMD 6 (9.2) 9 (13.6) 15 (11.5) 
MDS-U 11 (16.9 ) 2 ( 3.0) 13 (9.9) 
Cytogenetics (IPSS), N (%)    
Favorable 56 (86.1) 54 (81.8) 110 (84) 
Intermediate 9 (14.1) 12 (18.8) 21 (16) 
IPSS, N (%)    
Low 30 (46.1) 27 (40.9) 57 (43.5) 
Intermediate-1 35 (54.7) 39 (60) 74 (56.5) 
Type of EPO resistance, N (%)    
Primary resistance 39 (60) 42 (63.6) 81 (61.8) 
Relapse 26 (40) 24 (36.4) 50 (38.1) 
Serum EPO level, U/L median [IQR]  
134 [69-306] 
 
185 [72.5-498.5] 
 
225.5 [69-498.5] 
Number of RBC units transfused/8wk, 
median [IQR] 
 
6 [4-8] 
 
6 [4-8] 
 
6 [4-8] 
Genetic characteristics L arm (n=52)  LE arm (n=47) All (n=99) 
CRBN rs1672753 polymorphism, N (%) 
A/A 
G/A or G/G 
 
35 (67.3) 
17 (32.7) 
 
34 (72.3) 
13 (27.6) 
 
69 (69.7) 
30 (30.3) 
 
 
IQR, interquartile range; M/F, male/female; WHO, world health organisation; RARS, 
refractory anemia with ring sideroblasts; RCMD-RS, refractory cytopenia with multilineage 
dysplasia; RS, ring sideroblasts; RAEB, refractory anemia with excess blasts; MDS-U, MDS 
unclassified; IPSS, international prognostic scoring system; EPO, erythropoietin; RBC, red 
blood cells; CRBN, cereblon gene. 
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Table 2: Erythroid response according to IWG 2006 criteria (primary endpoint), in the 
two randomized arms  
 L Arm 
(N=65) 
LE Arm 
(N=66) 
p value 
 Intent-to-treat analysis, N (%)    
Assuming missing outcomes as failures : 
Primary analysis  
15 (23.1) 26 (39.4) 0.044 
Sensitivity analyses, N (%)    
Assuming missing outcomes as failures in 
the L arm and responses in the LE arm 
15 (23.1) 42 (63.6) 0.0001 
Assuming missing outcomes as responses in 
the L arm and failures in the LE arm 
31 (47.7) 26 (39.4) 0.38 
Assessed responses, N (%) 49 (75.4) 50 (75.8) N=99 
Reasons for non-observed outcomes*, N 
(%) 
16 (24.6) 16 (24.2) N=32 
Adverse events 12 9 21 
Progression/death 1 (death after 2 cycles) 3 4 
Investigator’s decision 0 2 2 
Patient’s decision 2 1 3 
Suicide  1 (after 2 cycles) 0 1 
Loss to follow-up 0 1 (after 2 cycles) 1 
 
 
*All due to treatment discontinuation before the end of the 4
th
 course;  
L, Lenalidomide; LE, Lenalidomide + Erythropoietin.  
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Table 3: Prognostic factors of erythroid response: univariate analysis 
Variable 
Number of 
patients 
Number of 
HI-E  
response 
% HI-
E    OR (95%CI) P-value 
Gender  
Female  
Male 
43 
88 
10 
31 
23.3 
35.3  
1.00 
1.8 (0.78-4.12) 0.17 
Age 
<70 years 
≥70 years 
45 
86 
12 
29 
26.7 
33.7  
1.00 
1.4 (0.63-3.11) 0.41 
WHO classification 
RARS 
RCMD-RS 
RAEB1 
RCMD 
MDS-U 
57 
24 
22 
15 
13 
17 
5 
8 
8 
3 
29.8 
20.8 
36.4 
53.3 
23.1  
1.00 
0.6 (0.20-1.93) 
1.3 (0.48-3.79) 
2.7 (0.84-8.60) 
0.7 (0.17-2.89) 
 
0.41 
0.58 
0.095 
0.63 
Cytogenetics (IPSS) 
Intermediate  
Favorable 
21 
110 
7 
34 
33.3 
30.9  
1.00 
0.89 (0.33-2.42) 0.83 
Risk (IPSS)  
Intermediate-1  
Low 
74 
55 
25 
16 
33.8 
29.1  
1.00 
0.80 (0.38-1.71) 0.57 
Type of EPO resistance  
Primary  
Relapse  
 
50 
81 
 
18 
23 
 
36.0 
28.4  
 
1.00 
1.42 (0.67-3.01) 
 
0.36 
Serum EPO level 
≥100U/L  
< 100U/L 
70 
34 
15 
16 
21.4 
47.1  
1.00 
3.3 (1.35-7.9) 0.0087 
CRBN rs1672753 SNP  
A/A 
G/A or G/G  
69 
30 
23 
17 
38.3 
56.7  
1.00 
2.6 (1.09-6.3) 0.032 
 
 
 
RARS, refractory anemia with ring sideroblasts; RCMD, refractory cytopenia with 
multilineage dysplasia; RS, ring sideroblasts; RAEB, refractory anemia with excess blasts; 
MDS-U, MDS unclassified; IPSS, international prognostic scoring system; EPO, 
erythropoietin; CRBN, cereblon gene. 
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Table 4 : Multivariate analysis 
Patients tested for CRBN rs1672753 polymorphism 
(N=99) 
IWG 2006 
responses 
OR (IC95%) 
 
Multivariate 
analysis 
p 
LE versus L treatment 5.0 [1.64-15.1] 0.0047 
M/F 1.79 [0.78 ; 4.12]  NS 
IPSS Low versus Intermediate-1 0.80 [0.38 ; 1.71] NS 
Type of EPO resistance : primary versus relapse 1.42 [0.67 ; 3.01] NS 
Serum EPO level < 100 U/L versus ≥ 100 U/L 4.05 [1.3-12.6]  0.016 
CRBN A/A versus G/A or G/G 0.38 [0.16 ; 0.92] 0.026 
 
CRBN, cereblon gene ; LE, Lenalidomide + Erythropoietin ; L, Lenalidomide  
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Table 5 : Grade 3 and 4 adverse events during the first four cycles 
Non hematological grade 3-4 AEs before the end of  the 4th cycle 
(number of patients) 
L Arm  
N=65 
LE Arm  
N= 66 
Deep vein thrombosis  3 1 
Acute coronary syndrome 1 - 
Cardiac failure 3 3 
Diarrhea  1 3 
Bowel obstruction 2 - 
Rash 2 - 
Dyspnea 2 2 
Pleural effusion - 1 
Renal failure  - 2 
Gout  - 2 
Other metabolic disorders - 1 
Fatigue 2 3 
Hematological grade 3-4 AEs before the end of  the 4th cycle (number of patients)   
Neutropenia 14  12  
Thrombocytopenia  2  5 
 
 
AE, adverse event; L, Lenalidomide; LE, Lenalidomide + Erythropoietin.  
INCLUSION CRITERIA
- Lower risk MDS
Low and Int-1 IPSS
- Without del 5q
- Transfusion dependence
≥ 4 RBC units/8 weeks 
before randomization
-ESA failure 
≥ 12 consecutive weeks
≥ 60,000 UI or 250µg/week
or relapse after ESA response
LEN 
10 mg/day
x 21days
every 28 days
LEN 
10 mg/day
x 21days
every 28 days
+
EPO beta
60,000  U/Week
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Toma et al. - Figure 1 : GFM LENEPO 2008 study – Schema and treatment plan
Patients enrolled (n=132)
Received 4 cycles of LEN alone  
(n=49 )
Discontinued intervention (n=16)
¨ Adverse events (n=12)
¨ Patient's or investigator's decision (n=2)
¨ Unknown reason (n=2)
Randomly assigned to LEN alone treatment (n=66)
¨ Received allocated intervention (n= 65)
¨ Did not receive allocated intervention 
(n=1, consent withdrawal)
Discontinued intervention (n=16)
¨ Adverse events (n=9)
¨ Patient's or investigator's decision (n=3)
¨ Death (n=3)
¨ Unknown reason (n=1)
Randomly assigned to LEN+EPO treatment (n=66)
¨ Received allocated intervention (n= 66)
¨ Did not receive allocated intervention 
(n=0)
Received 4 cycles of LEN+EPO
(n=50 )
Allocation
Evaluation after 4 cycles
Induction 
treatment
(4 cycles)
Enrollment
Toma et al. - Figure 2 : CONSORT 2010 Flow diagram 
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